Fox News Flash top headlines are here. Check out what's clicking on Foxnews.com. Eating avocados two or more times a week is associated with a lower risk of cardiovascular disease and coronary heart disease, according to researchers. In a study published in the Journal of the American Heart Association on Wednesday, the authors found that the replacement of margarine, butter, egg, yogurt, cheese and processed meats with avocado was also beneficial for the heart. The study examined data from more than 68,000 women from the Nurses' Health Study and more than 41,000 men from the Health Professionals Follow‐up Study who were free of cancer, coronary heart disease and stroke at baseline.
A new study published, Automated Echocardiographic Detection of Severe Coronary Artery Disease Using Artificial Intelligence, found that Ultromics' EchoGo platform, powered by Artificial Intelligence (AI), significantly improved the accuracy and confidence in coronary artery disease (CAD) detection from a stress echocardiogram. The study, published in JACC: Cardiovascular Imaging, revealed doctors are more confident in CAD diagnoses with the support of EchoGo. Further, the study revealed that the EchoGo AI improved the sensitivity of detection of the disease by over 10%, which brings the effectiveness of stress echocardiography – as a modality – on par with much more expensive and invasive diagnostic procedures. Ultromics' has developed an AI algorithm that automatically analyzes stress echocardiograms and tells the clinician whether that patient is at risk of coronary artery disease. The study assessed Ultromics' deep learning algorithms trained on hundreds of thousands of data to predict CAD risk, and was able to distinguish the CAD risk in patients with 10% more sensitivity than manual analysis.
Imagine being able to record yourself reading and then having your clinician use those recordings to screen for various diseases, even from thousands of miles away. This technology may sound like science fiction, but Mayo Clinic researchers are using artificial intelligence (AI) to discover and test what the voice can reveal about a patient's heart health. In a recent study, the research team used an AI trained for specific vocal biomarkers to accurately predict which patients were more likely to have clogged arteries that led to further heart problems. Dr. Jaskanwal Deep Sara, a cardiology fellow at Mayo Clinic, is the study's lead author. A news release from the American College of Cardiology (ACC) explains the study methods and findings that were published online first in the medical journal Mayo Clinic Proceedings.
Screening for significant aortic stenosis was fast and effective through the assessment of phonocardiograms by a digital stethoscope and machine learning, according to results presented at the American Society of Echocardiography Scientific Sessions. "A machine-learning algorithm trained on heart sounds can rapidly and accurately detect a murmur in patients with clinically significant aortic stenosis," Steve Pham, MD, vice president of clinical and research affairs at Eko Devices, told Cardiology Today. "Front-line clinicians may be able to use Eko stethoscopes (Eko CORE) with this algorithm to refer patients for echocardiography to confirm aortic stenosis." Brent E. White, MD, of the Bluhm Cardiovascular Institute at Northwestern Memorial Hospital in Chicago, and colleagues analyzed 639 recordings from 161 patients who were undergoing transthoracic echocardiography. The 15-second phonocardiogram recordings were obtained from the digital stethoscope, which is wirelessly paired with a mobile app (Eko Mobile).
Artificial intelligence that rapidly spots blocked arteries in CT scans could be rolled out on the NHS next year. The technology, created by $1.5bn US medtech start-up Heartflow, virtually models a patient's heart and blood vessels from CT scans on an iPad or iPhone. It can then simulate blood flow and model potential blockages so doctors can draw up early treatments for coronary heart disease. Earlier this month, the company gained approval from the US Food and Drug Administration. It believes it will receive clearance in the UK for its Planner technology before the end of the year to pave the way for a launch by mid-2020.